Literature DB >> 10573171

A model for vaccinia virus pathogenesis and immunity based on intradermal injection of mouse ear pinnae.

David C Tscharke1, Geoffrey L Smith1.   

Abstract

Vaccinia virus (VV) proteins that interfere with the host response to infection are of interest because they provide insight into virus-host relationships and may affect the safety and immunogenicity of recombinant VV (rVV) vaccines. Such vaccines need assessment in animal models and with this aim a model of VV infection based on intradermal injection of BALB/c ear pinnae was developed and characterized. In this model, the outcome of infection is affected by the dose of virus inoculated but virus spread is minimal and the mice suffer no signs of systemic illness. Cellular and humoral immune responses to these infections were measured readily and were independent of virus dose over a 100-fold range. Thus the model seems suitable for the analysis of the safety and immunogenicity of VV mutants lacking specific immunomodulatory proteins or bearing foreign antigens.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10573171     DOI: 10.1099/0022-1317-80-10-2751

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  47 in total

1.  Comparable polyfunctionality of ectromelia virus- and vaccinia virus-specific murine T cells despite markedly different in vivo replication and pathogenicity.

Authors:  Adam R Hersperger; Nicholas A Siciliano; Laurence C Eisenlohr
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

2.  The vaccinia virus superoxide dismutase-like protein (A45R) is a virion component that is nonessential for virus replication.

Authors:  F Almazán; D C Tscharke; G L Smith
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 3.  Initiation of primary anti-vaccinia virus immunity in vivo.

Authors:  Matthew A Fischer; Christopher C Norbury
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

4.  MyD88-dependent immunity to a natural model of vaccinia virus infection does not involve Toll-like receptor 2.

Authors:  Michael L Davies; Janet J Sei; Nicholas A Siciliano; Ren-Huan Xu; Felicia Roscoe; Luis J Sigal; Laurence C Eisenlohr; Christopher C Norbury
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

5.  A comparison of the effect of molluscum contagiosum virus MC159 and MC160 proteins on vaccinia virus virulence in intranasal and intradermal infection routes.

Authors:  Sunetra Biswas; Geoffrey L Smith; Edward J Roy; Brian Ward; Joanna L Shisler
Journal:  J Gen Virol       Date:  2018-02       Impact factor: 3.891

6.  Vaccinia virus A43R gene encodes an orthopoxvirus-specific late non-virion type-1 membrane protein that is dispensable for replication but enhances intradermal lesion formation.

Authors:  Cindy L Sood; Bernard Moss
Journal:  Virology       Date:  2009-11-08       Impact factor: 3.616

7.  Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens.

Authors:  Pavlo Sakhatskyy; Shixia Wang; Chuanyou Zhang; Te-Hui Chou; Michael Kishko; Shan Lu
Journal:  Virology       Date:  2007-10-24       Impact factor: 3.616

8.  Vaccinia virus lacking the Bcl-2-like protein N1 induces a stronger natural killer cell response to infection.

Authors:  Nathalie Jacobs; Nathan W Bartlett; Richard H Clark; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2008-11       Impact factor: 3.891

9.  Vaccinia virus protein C16 acts intracellularly to modulate the host response and promote virulence.

Authors:  Aodhnait S Fahy; Richard H Clark; Emily F Glyde; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2008-10       Impact factor: 3.891

10.  Camelpox virus encodes a schlafen-like protein that affects orthopoxvirus virulence.

Authors:  Caroline Gubser; Rory Goodbody; Andrea Ecker; Gareth Brady; Luke A J O'Neill; Nathalie Jacobs; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2007-06       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.